Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 9, 2025Open Access

Tumor NLRP3 Amplification Promotes Immunotherapy Resistance by Suppressing MHC Class I Expression

View Full Paper
Ask AI
Bookmark
Share

Authors

BTBala TheivanthiranNYNagendra Sastry YarlaKVKaylee Villareal

Discussion

Loading...

Member takes

Implication

Analysis reveals nlrp3 amplification reduces mhc class i levels in melanoma and gastroesophageal cancers, indicating a potential therapeutic target.

Key Points

  • NLRP3 amplification promotes immunotherapy resistance by reducing MHC class I levels in tumors.
  • Data show elevated NLRP3 signaling activity correlates with checkpoint inhibitor resistance in melanoma and GE adenocarcinoma.
  • Pre-clinical models confirm that inhibiting NLRP3 enhances MHC class I surface expression, suggesting a new treatment strategy.
  • The tumor NLRP3 inflammasome may serve as a biomarker and potential therapeutic target in overcoming cancer resistance.

Cite This Study

Theivanthiran et al. (2025) studied this question.

synapsesocial.com/papers/68e70da790569dd607ee59e3https://doi.org/10.1101/2025.10.06.25337175
View Full Paper
Ask AI
Bookmark
Share